左卡尼汀减轻头颈癌放化疗所致毒性:一项随机研究
在印度北部三级放疗中心开展的随机研究,将接受同步放化疗的头颈鳞癌患者分为口服左卡尼汀500 mg每日三次加对症治疗组与仅对症治疗组。结果显示左卡尼汀组皮炎、黏膜炎、喉反应和吞咽困难的严重程度降低且发生延迟,口干无获益,治疗反应两组相当,但作者指出需更大规模多中心随机试验证实。
要点
- 左卡尼汀组皮炎、黏膜炎、喉反应及吞咽困难的严重程度显著降低且发生延迟。
- 左卡尼汀组治疗后简明疲劳量表均值为37.22,对照组为52.24(P=0.042)。
- 对照组28.75%患者白蛋白<3.4 g/dL,左卡尼汀组无此类患者。
核心结论
- 左卡尼汀可用于接受同步放化疗的头颈鳞癌患者以减轻治疗相关毒性,但需更大规模多中心随机试验证实该结论。
研究设计与样本
- 研究在印度北部一家三级放疗中心开展,时间为2018年8月至2020年。
- 所有患者被随机分为研究组和对照组。
- 研究组口服左卡尼汀500 mg每日三次,并接受放化疗所致毒性的对症治疗。
- 对照组仅接受放化疗所致毒性的对症治疗。
- 治疗期间每两周采用RTOG标准评估毒性。
主要发现
- 皮炎、黏膜炎、喉反应和吞咽困难的严重程度显著降低且发生延迟,但口干未见此类获益。
- 两组治疗反应相当。
- 研究组治疗后简明疲劳量表均值为37.22,对照组为52.24(P=0.042)。
- 对照组28.75%患者白蛋白水平<3.4 g/dL,研究组无此类患者。
- 研究组中位体重下降为5.2%,对照组为7.4%。
关键数值与推荐
- 毒性评估采用RTOG标准,每两周一次。
- 疲劳评估采用简明疲劳量表(BFI)。
- 生活质量评估采用EORTC-QLQ-C30问卷。
- 原发肿瘤及颈部淋巴结疗效评估采用RECIST 1.1。
- 营养评估通过比较治疗期间血红蛋白、白蛋白和体重下降进行。
临床怎么用
- 作者认为左卡尼汀可用于接受同步放化疗的头颈鳞癌患者以减轻治疗相关毒性。
- 作者指出需更大规模多中心随机试验证实该结论。
局限性
- 原文指出需更大规模多中心随机试验证实该结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment related toxicities for management of cancer lead to significant deterioration in the quality of life, increased morbidity, hospital admissions, and increased treatment interruptions. We carried out this study, to reduce treatment related toxicities without compromising treatment efficacy. OBJECTIVES: Evaluate L-carnitine in reducing toxicities in HNSCC patients undergoing concurrent chemoradiation. METHODOLOGY: Study conducted in the Department of Radiotherapy tertiary care center in Northern India from August 2018 to 2020. All patients were randomized into the study arm and control arm; the study arm received oral L-carnitine 500 mg thrice daily, with symptomatic treatment for chemoradiotherapy-induced toxicity. The control arm received only symptomatic treatment for chemoradiation-induced toxicities. Toxicity assessment was done biweekly during treatment using RTOG (Radiation Therapy Oncology Group) criteria for toxicity assessment. Nutritional assessment was done by comparing hemoglobin, albumin, and weight loss during treatment. Fatigue was assessed using the Brief Fatigue Inventory (BFI) and the quality of life was assessed using the EORTC-QLQ-C30 questionnaire. Response evaluation for the primary tumor and neck nodes was done using RECIST 1.1. RESULTS: Significant decrease in severity and delay in onset of dermatitis, mucositis, laryngeal reactions, and dysphagia were observed; however, no such benefit was seen in xerostomia. Treatment response was comparable in both arms. Mean post-treatment BFI in the test arm versus control arm was 37.22 and 52.24 (p-value 0.042), respectively. 28.75% of patients in the control arm and none in the study arm had albumin levels < 3.4 g/dL. Median weight loss in the test arm was 5.2% and in the control arm was 7.4%. Hospital admission was significantly less in the test arm. CONCLUSION: L-carnitine can be given to HNSCC patients receiving concurrent chemoradiation to lessen treatment related toxicity, but larger, multicentric randomized trials required to substantiate this conclusion.
引用
- Puja K, Singh K, Yadav I, et al. L-Carnitine to Reduce Chemoradiotherapy-Induced Toxicity in Head and Neck Cancer: A Randomized Study. Head Neck. 2025. PMID: 40536003. doi:10.1002/hed.28221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。